You are here
GMSI Award 2015 – Dynamics of M1/M2 polarization of microglia in MS: a PET imaging study
Elga de Vries
This lecture was given at the Grant for Multiple Sclerosis Innovation Awards Event, 8th October 2015. The GMSI award was supported by Merck KGaA, Darmstadt, Germany. Dr. de Vries is an award winner and works at the Amsterdam MS centre, in Amsterdam Free University.
Microglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective. Visualisation in patients was needed, possibly with PET. It was still unclear how these phenotypes differed during the progression of the disease. The aim of the grant was to develop tools to visualise the M2 phenotype.
Dr. de Vries said that P2X7 was a purinergic receptor that might be a specific marker for M2 microglia. They were developing a specific tracer for this receptor and were validating it in vitro. Animal models would be followed by proof-of-concept in human MS patients. It would be examined whether expression of this receptor could be correlated with neuronal dysfunction. Autoradiography would be performed to test for selectivity. The tracer crossed the blood brain barrier. The ultimate goal would be to promote M1 vs. M2.
David Bates11/09/2015 - 10:41Professor Bates said that the GMSI [Grant for Multiple Sclerosis Innovation] was first awarded in 2013. Merck Serono provides research grants of up to 1 million Euros and thereby demonstrated its commitment to immunology...
Steven Hildemann11/09/2015 - 10:49Merck-Serono's pipeline focuses on difficult to treat diseases with a high unmet medical need, in the four areas of oncology, immuno-oncology, immunology and multiple sclerosis.
David Bates11/09/2015 - 11:00Professor Bates briefly summarised progress made by the recipients of the 2013 and 2014 grants.
Elga de Vries11/17/2015 - 13:31Microglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective.
Laura Airas11/17/2015 - 13:40In her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
GMSI Award 2015 – Driving microglia metabolism towards remyelination and restoration of brain damage in multiple sclerosis
Claudia Verderio11/17/2015 - 13:53According to Dr. Verderio, the new proposal stemmed from data on the biological activity of vesicles from microglia cells, on the proliferation, differentiation and myelination of oligodendrocyte precursor cells (OPCs).
Gabriele de Luca11/17/2015 - 14:03Dr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.